| Document |
Document Title |
|
JP2017025080A |
To provide pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) inhibitors effective in treatment of neurodegenerative diseases such as tauopathies including Alzheimer's disease.The invention provides pharmaceutical compo...
|
|
JP6067031B2 |
The present invention relates to sulfonamide derivatives of formula (I): or a pharmaceutically acceptable salts thereof, wherein Z, R1a, R1b, R2, R3, R4 and R5 are as defined in the description, and to their use in medicine, to compositi...
|
|
JP6051457B2 |
Azetidine derivatives of which the following is exemplary and their use in the treatment of obesity, diabetes or dyslipidemia.
|
|
JP6053795B2 |
The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other d...
|
|
JP6048406B2 |
The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
|
|
JP6038297B2 |
and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and metho...
|
|
JP6034412B2 |
Disclosed is a process for the preparation of the compound of formula (471)
|
|
JP6019126B2 |
The invention provides organonitro thioether compounds, compositions containing such compounds, isolated organonitro thioether compounds and methods for using such compounds and compositions to treat cancer in a patient. Exemplary organo...
|
|
JP2016533375A |
The present invention relates to aminotetralin derivatives and aminoindane derivatives of formulas (I) (I) or physiologically acceptable salts of the derivatives. The present invention relates to pharmaceutical compositions containing su...
|
|
JP6006308B2 |
There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates us...
|
|
JP2016172717A |
To provide compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, and methods for their use as pharmaceutical compositions.The present invention provides a compound represented by formula...
|
|
JP2016529238A |
The present invention relates to a compound of formula (I). [Chemical 1]Provided are a method for producing a compound of the present invention and a therapeutic use thereof. The present invention further provides a combination of a phar...
|
|
JP5995988B2 |
Compounds according to formula (I) or formula (II) wherein R1 and R2, independently from each other, are chosen among hydrocarbons having from 1 carbon atom up to 30 carbon atoms, with the proviso that at least one of R1 and R2 are chose...
|
|
JP5991313B2 |
[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for So...
|
|
JP2016164159A |
To provide compounds that are novel modulators, e.g., activators or agonists, of the human calcium sensing receptor (CaSR) and effective in treatment of chronic kidney disease and osteoporosis.The invention provides a compound represente...
|
|
JP5984218B2 |
The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), interme...
|
|
JP5977837B2 |
The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of th...
|
|
JP5969958B2 |
|
|
JP2016145173A |
To provide a method for efficiently producing high purity (3R,4S)-1-(4-fluorophenyl)-[3(S)-hydroxy-3-(4-fluorophenyl)p
ropyl]-(4-hydroxyphenyl)-2-azetidinone in which the amount of specified impurities is reduced.In the presence of palla...
|
|
JP5968537B2 |
A process for the production of ezetimibe and intermediates used in said process are disclosed. A kind of Morita-Baylis-Hillman adduct can be altered to chiral carboxylic acid derivatives of ²-arylamino ±-methylene with high activity a...
|
|
JP5957646B2 |
The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant inv...
|
|
JP2016132638A |
To provide an organic inorganic perovskite compound having high resistance to water, and further to provide a light emitter and an electronic device having high durability against water using the compound.There is provided an organic ino...
|
|
JP2016521259A |
The present invention comprises the substitutions N-biphenyl-3-acetylamino-benzamide and N- [3- (acetylamino) phenyl] -biphenyl-carboxamide of the general formula (I) described and defined herein, said compounds. Methods of preparation, ...
|
|
JP5944825B2 |
The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. X in formula (I) is selected from -OCF 3 and -OCH 3 . The other variables for Structural Formula (I) ar...
|
|
JP5941110B2 |
S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
|
|
JP2016517412A |
The present invention relates to the compound for FASN prevention, constituents, those composition, application, and an antidote. An example of the compound of the present invention is shown below. [Drawing 1]
|
|
JP5927518B2 |
An N1-cyclic amine-N5-substituted phenyl biguanide derivative of Formula 1 or a pharmaceutically acceptable salt thereof, a method of manufacturing the same, and a pharmaceutical composition including the biguanide derivative or the phar...
|
|
JP5928915B2 |
A compound having an ability to bind to an S1P receptor (particularly EDG-6, preferably EDG-1 and EDG-6), for example, the compound represented by formula (I) of the present invention, a salt thereof, a solvate thereof or a prodrug there...
|
|
JP5923110B2 |
The invention provides methods of making and using compounds of the formula: or a pharmaceutically acceptable salt thereof; wherein n is an integer between 1 and 2 inclusively; m is an integer between 0 and 2 inclusively; X is selected f...
|
|
JP2016513681A |
The present invention relates to a compound contained in formula (I), a pharmaceutical composition thereof, a method for inhibiting LTA-4 hydrolase, and a method for treating diseases and disorders ameliorated by inhibition of LTA4-h act...
|
|
JP5913296B2 |
The disclosure relates to hexafluoroisopropyl carbamate derivatives of general formula (I): in which: R, Z, A, m, and n are as defined in the disclosure; in the form of the base or of an addition salt with an acid, and to the preparation...
|
|
JP2016512195A |
In one mode, the present invention is formula (I) (inside of a formula, R).1*R5and as X having been defined by this specification -- it is -- it is related with a compound which it has, or its salt permitted pharmacologically. These comp...
|
|
JP2016053055A |
To provide a prophylactic or therapeutic agent for diabetes, diabetic complications, diabetic microangiopathy complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, heart failure, ca...
|
|
JP5893610B2 |
The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for use, and their pharmaceutical compositions.
|
|
JP5893558B2 |
Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
|
|
JP5887207B2 |
|
|
JP5886873B2 |
The present invention relates to novel N-substituted azetidine derivatives
|
|
JP5876140B2 |
The present invention relates to novel substituted phenoxyethylamine derivatives, useful as modulators of cortical and basal ganglia dopaminergic and N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission. In other...
|
|
JP5876419B2 |
The present invention relates to substituted aryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.
|
|
JP2016505587A |
The present invention isWith respect to the novel compounds (in the formula, the variable elements have the meanings set forth in the claims in free and salt form) and, as appropriate, their enantiomers and geometric isomers. The compoun...
|
|
JP5856211B2 |
Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceut...
|
|
JP2016017035A |
To provide a method for producing a metal chelate forming compound.The method for producing a metal chelate forming compound of a deoxymugineic acid and the like being effective in the solubilization of Fe component in soil by using oliv...
|
|
JP5848698B2 |
The present invention relates to inhibitors of 11- ß-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, centr...
|
|
JP5846909B2 |
The present invention relates to compounds defined by formula (I) wherein the group R is defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase ...
|
|
JP2015232045A |
To provide certain inhibitors of MEK which are useful in treatment of hyperproliferative diseases, such as cancer, in mammals.Disclosed are compounds of a formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compo...
|
|
JP2015533782A |
It is an inhibitor of HBV replication of formula (I) and contains its steric chemical isomers, as well as salts, hydrates and solvates, in formulas B, R.1, R2And R4Has the meaning as defined herein. The present invention also relates to ...
|
|
JP5817763B2 |
A compound having an ability to bind to an S1P receptor (particularly EDG-6, preferably EDG-1 and EDG-6), for example, the compound represented by formula (I) of the present invention, a salt thereof, a solvate thereof or a prodrug there...
|
|
JP5816557B2 |
The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of s...
|
|
JP5813101B2 |
The compounds of the present invention are represented by the following formula (I): wherein the substituents R1, R2, R3, R4, (R5)m, R6, A, X, and Y are as defined herein. The compounds are useful in methods of treating a disorder which ...
|
|
JP5813223B2 |
There is described a novel group of cyclic amine derivative compounds, having an EP4 receptor antagonistic activity and specifically pharmaceutical compounds which are useful for the treatment or alleviation of Prostaglandin E mediated d...
|
